Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease.

导出 OA

翻译打印收藏纠错

第一作者： Fiona,Kerr

第一单位： Institute of Healthy Ageing, and GEE, University College London, Darwin Building, Gower Street, London, United Kingdom.

作者： Fiona,Kerr ^[1] ; Oyinkan,Sofola-Adesakin ^[1] ; Dobril K,Ivanov ^[2] ; Jemma,Gatliff ^[3] ; Beatriz,Gomez Perez-Nievas ^[4] ; Hélène C,Bertrand ^[3] ; Pedro,Martinez ^[1] ; Rebecca,Callard ^[1] ; Inge,Snoeren ^[5] ; Helena M,Cochemé ^[1] ; Jennifer,Adcott ^[5] ; Mobina,Khericha ^[6] ; Jorge Iván,Castillo-Quan ^[1] ; Geoffrey,Wells ^[1] ; Wendy,Noble ^[5] ; Janet,Thornton ^[1] ; Linda,Partridge ^[5]

作者单位： Institute of Healthy Ageing, and GEE, University College London, Darwin Building, Gower Street, London, United Kingdom. ^[1] European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom. ^[2] UCL School of Pharmacy, University College London, 29/39 Brunswick Square, London, United Kingdom. ^[3] Maurice Wohl Clinical Neuroscience Institute, King's College London, London, United Kingdom. ^[4] Max Planck Institute for Biology of Ageing, Köln, Germany. ^[5] MRC London Institute of Medical Sciences, Imperial College London, Du Cane Road, London, United Kingdom. ^[6]